Publikation: Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
Major practical constraints on neural grafting in Parkinson's disease are the shortage of human donor tissue and the great loss of dopamine neurons during the grafting procedure. The vast majority of implanted embryonic dopamine neurons are believed to die within a few days of transplantation surgery, at least in part through apoptosis. We have previously found that survival of nigral grafts in rodents can be significantly augmented by pretreatment with the caspase inhibitor Ac-YVAD-cmk or by lazaroids (lipid peroxidation inhibitors). We now report that pretreatment with the caspase inhibitor Ac-DEVD-cmk, but not z-VAD-fmk, results in a significantly improved survival of transplanted dopamine neurons of similar magnitude to that achieved in this study using Ac-YVAD-cmk (both 220–230% of control). In addition, we found that treatment of the graft tissue with tirilazad mesylate (a lazaroid allowed for clinical use) almost doubled the survival of grafted dopamine neurons. When Ac-YVAD-cmk and tirilazad mesylate treatments were combined, the number of surviving dopamine neurons increased significantly further to 280% of control. Importantly, the same combination of neuroprotectants enhanced the survival of human dopamine neurons xenotransplanted to immunosuppressed rats (to 240% of control). In conclusion, these results suggest that combining treatments that counteract oxidative stress and caspase activation is a valuable strategy to enhance nigral graft survival that should be considered for clinical application.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
HANSSON, Oskar, Roger F. CASTILHO, Gabriele S. KAMINSKI SCHIERLE, Jenny KARLSSON, Pierluigi NICOTERA, Marcel LEIST, Patrik BRUNDIN, 2000. Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons. In: Experimental Neurology. Elsevier. 2000, 164(1), pp. 102-111. ISSN 0014-4886. eISSN 1090-2430. Available under: doi: 10.1006/exnr.2000.7406BibTex
@article{Hansson2000-07Addit-51272, year={2000}, doi={10.1006/exnr.2000.7406}, title={Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons}, number={1}, volume={164}, issn={0014-4886}, journal={Experimental Neurology}, pages={102--111}, author={Hansson, Oskar and Castilho, Roger F. and Kaminski Schierle, Gabriele S. and Karlsson, Jenny and Nicotera, Pierluigi and Leist, Marcel and Brundin, Patrik} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/51272"> <dc:contributor>Brundin, Patrik</dc:contributor> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-10-09T07:15:28Z</dcterms:available> <dc:contributor>Leist, Marcel</dc:contributor> <dc:contributor>Castilho, Roger F.</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dc:creator>Nicotera, Pierluigi</dc:creator> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:contributor>Nicotera, Pierluigi</dc:contributor> <dc:creator>Karlsson, Jenny</dc:creator> <dc:creator>Kaminski Schierle, Gabriele S.</dc:creator> <dc:creator>Hansson, Oskar</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <dcterms:issued>2000-07</dcterms:issued> <dc:contributor>Karlsson, Jenny</dc:contributor> <dcterms:title>Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons</dcterms:title> <dc:creator>Leist, Marcel</dc:creator> <dc:contributor>Hansson, Oskar</dc:contributor> <dc:creator>Brundin, Patrik</dc:creator> <dc:creator>Castilho, Roger F.</dc:creator> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-10-09T07:15:28Z</dc:date> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/51272"/> <dc:language>eng</dc:language> <dc:rights>terms-of-use</dc:rights> <dc:contributor>Kaminski Schierle, Gabriele S.</dc:contributor> <dcterms:abstract xml:lang="eng">Major practical constraints on neural grafting in Parkinson's disease are the shortage of human donor tissue and the great loss of dopamine neurons during the grafting procedure. The vast majority of implanted embryonic dopamine neurons are believed to die within a few days of transplantation surgery, at least in part through apoptosis. We have previously found that survival of nigral grafts in rodents can be significantly augmented by pretreatment with the caspase inhibitor Ac-YVAD-cmk or by lazaroids (lipid peroxidation inhibitors). We now report that pretreatment with the caspase inhibitor Ac-DEVD-cmk, but not z-VAD-fmk, results in a significantly improved survival of transplanted dopamine neurons of similar magnitude to that achieved in this study using Ac-YVAD-cmk (both 220–230% of control). In addition, we found that treatment of the graft tissue with tirilazad mesylate (a lazaroid allowed for clinical use) almost doubled the survival of grafted dopamine neurons. When Ac-YVAD-cmk and tirilazad mesylate treatments were combined, the number of surviving dopamine neurons increased significantly further to 280% of control. Importantly, the same combination of neuroprotectants enhanced the survival of human dopamine neurons xenotransplanted to immunosuppressed rats (to 240% of control). In conclusion, these results suggest that combining treatments that counteract oxidative stress and caspase activation is a valuable strategy to enhance nigral graft survival that should be considered for clinical application.</dcterms:abstract> </rdf:Description> </rdf:RDF>